Medicus Pharma announces strategic collaboration with Gorlin Syndrome Alliance

Medicus Pharma (MDCX) announces a strategic collaboration with the Gorlin Syndrome Alliance, GSA, to advance compassionate access to SKINJECT, the Company’s investigational doxorubicin containing microneedle arrays, D-MNA, for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration to allow patients with multiple, recurrent, or inoperable basal cell carcinomas to access SKINJECT under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT in this rare disease population.